Selected research
Market Structure
Global Ornithine-Transcarbamylase Deficiency Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Ornithine-Transcarbamylase Deficiency market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Ornithine-Transcarbamylase Deficiency is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Ornithine-Transcarbamylase Deficiency is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Ornithine-Transcarbamylase Deficiency is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Ornithine-Transcarbamylase Deficiency is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Ornithine-Transcarbamylase Deficiency include Lucane Pharma SA, PhaseRx Inc, Promethera Biosciences SA, Selecta Biosciences Inc, Translate Bio Inc, Ultragenyx Pharmaceutical Inc and Unicyte AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Ornithine-Transcarbamylase Deficiency market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Ornithine-Transcarbamylase Deficiency and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Ornithine-Transcarbamylase Deficiency sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Ornithine-Transcarbamylase Deficiency market size, projected growth trends, production technologies, key applications, and end-use industries.
Ornithine-Transcarbamylase Deficiency Segment by Company
Lucane Pharma SA
PhaseRx Inc
Promethera Biosciences SA
Selecta Biosciences Inc
Translate Bio Inc
Ultragenyx Pharmaceutical Inc
Unicyte AG
Ornithine-Transcarbamylase Deficiency Segment by Type
SHP-641
SEL-313
PRX-OTC
DTX-301
Others
Ornithine-Transcarbamylase Deficiency Segment by Application
Hospital
Clinic
Others
Ornithine-Transcarbamylase Deficiency Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ornithine-Transcarbamylase Deficiency market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ornithine-Transcarbamylase Deficiency and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ornithine-Transcarbamylase Deficiency.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Ornithine-Transcarbamylase Deficiency market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ornithine-Transcarbamylase Deficiency manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Ornithine-Transcarbamylase Deficiency in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Ornithine-Transcarbamylase Deficiency in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- SHP-641
- SEL-313
- PRX-OTC
- DTX-301
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Lucane Pharma SA
- PhaseRx Inc
- Promethera Biosciences SA
- Selecta Biosciences Inc
- Translate Bio Inc
- Ultragenyx Pharmaceutical Inc
- Unicyte AG
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Ornithine-Transcarbamylase Deficiency Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Ornithine-Transcarbamylase Deficiency Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Ornithine-Transcarbamylase Deficiency Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Ornithine-Transcarbamylase Deficiency Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Ornithine-Transcarbamylase Deficiency Market Dynamics
- 2.1 Ornithine-Transcarbamylase Deficiency Industry Trends
- 2.2 Ornithine-Transcarbamylase Deficiency Industry Drivers
- 2.3 Ornithine-Transcarbamylase Deficiency Industry Opportunities and Challenges
- 2.4 Ornithine-Transcarbamylase Deficiency Industry Restraints
3 Ornithine-Transcarbamylase Deficiency Market by Manufacturers
- 3.1 Global Ornithine-Transcarbamylase Deficiency Revenue by Manufacturers (2021-2026)
- 3.2 Global Ornithine-Transcarbamylase Deficiency Sales by Manufacturers (2021-2026)
- 3.3 Global Ornithine-Transcarbamylase Deficiency Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Ornithine-Transcarbamylase Deficiency Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Ornithine-Transcarbamylase Deficiency Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Ornithine-Transcarbamylase Deficiency Manufacturers, Product Type & Application
- 3.7 Global Ornithine-Transcarbamylase Deficiency Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Ornithine-Transcarbamylase Deficiency Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Ornithine-Transcarbamylase Deficiency Players Market Share by Revenue in 2025
- 3.8.3 2025 Ornithine-Transcarbamylase Deficiency Tier 1, Tier 2, and Tier 3
4 Ornithine-Transcarbamylase Deficiency Market by Type
- 4.1 Ornithine-Transcarbamylase Deficiency Type Introduction
- 4.1.1 SHP-641
- 4.1.2 SEL-313
- 4.1.3 PRX-OTC
- 4.1.4 DTX-301
- 4.1.5 Others
- 4.2 Global Ornithine-Transcarbamylase Deficiency Sales by Type
- 4.2.1 Global Ornithine-Transcarbamylase Deficiency Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Ornithine-Transcarbamylase Deficiency Sales by Type (2021-2032)
- 4.2.3 Global Ornithine-Transcarbamylase Deficiency Sales Market Share by Type (2021-2032)
- 4.3 Global Ornithine-Transcarbamylase Deficiency Revenue by Type
- 4.3.1 Global Ornithine-Transcarbamylase Deficiency Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Ornithine-Transcarbamylase Deficiency Revenue by Type (2021-2032)
- 4.3.3 Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Type (2021-2032)
5 Ornithine-Transcarbamylase Deficiency Market by Application
- 5.1 Ornithine-Transcarbamylase Deficiency Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Ornithine-Transcarbamylase Deficiency Sales by Application
- 5.2.1 Global Ornithine-Transcarbamylase Deficiency Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Ornithine-Transcarbamylase Deficiency Sales by Application (2021-2032)
- 5.2.3 Global Ornithine-Transcarbamylase Deficiency Sales Market Share by Application (2021-2032)
- 5.3 Global Ornithine-Transcarbamylase Deficiency Revenue by Application
- 5.3.1 Global Ornithine-Transcarbamylase Deficiency Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Ornithine-Transcarbamylase Deficiency Revenue by Application (2021-2032)
- 5.3.3 Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Application (2021-2032)
6 Global Ornithine-Transcarbamylase Deficiency Sales by Region
- 6.1 Global Ornithine-Transcarbamylase Deficiency Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Ornithine-Transcarbamylase Deficiency Sales by Region (2021-2032)
- 6.2.1 Global Ornithine-Transcarbamylase Deficiency Sales by Region (2021-2026)
- 6.2.2 Global Ornithine-Transcarbamylase Deficiency Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Ornithine-Transcarbamylase Deficiency Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Ornithine-Transcarbamylase Deficiency Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Ornithine-Transcarbamylase Deficiency Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Ornithine-Transcarbamylase Deficiency Revenue by Region
- 7.1 Global Ornithine-Transcarbamylase Deficiency Revenue by Region
- 7.1.1 Global Ornithine-Transcarbamylase Deficiency Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Ornithine-Transcarbamylase Deficiency Revenue by Region (2021-2026)
- 7.1.3 Global Ornithine-Transcarbamylase Deficiency Revenue by Region (2027-2032)
- 7.1.4 Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Ornithine-Transcarbamylase Deficiency Revenue (2021-2032)
- 7.2.2 North America Ornithine-Transcarbamylase Deficiency Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Ornithine-Transcarbamylase Deficiency Revenue (2021-2032)
- 7.3.2 Europe Ornithine-Transcarbamylase Deficiency Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Ornithine-Transcarbamylase Deficiency Revenue (2021-2032)
- 7.4.2 Asia-Pacific Ornithine-Transcarbamylase Deficiency Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Ornithine-Transcarbamylase Deficiency Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Ornithine-Transcarbamylase Deficiency Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Lucane Pharma SA
- 8.1.1 Lucane Pharma SA Company Information
- 8.1.2 Lucane Pharma SA Business Overview
- 8.1.3 Lucane Pharma SA Ornithine-Transcarbamylase Deficiency Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Lucane Pharma SA Ornithine-Transcarbamylase Deficiency Product Portfolio
- 8.1.5 Lucane Pharma SA Recent Developments
- 8.2 PhaseRx Inc
- 8.2.1 PhaseRx Inc Company Information
- 8.2.2 PhaseRx Inc Business Overview
- 8.2.3 PhaseRx Inc Ornithine-Transcarbamylase Deficiency Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 PhaseRx Inc Ornithine-Transcarbamylase Deficiency Product Portfolio
- 8.2.5 PhaseRx Inc Recent Developments
- 8.3 Promethera Biosciences SA
- 8.3.1 Promethera Biosciences SA Company Information
- 8.3.2 Promethera Biosciences SA Business Overview
- 8.3.3 Promethera Biosciences SA Ornithine-Transcarbamylase Deficiency Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Promethera Biosciences SA Ornithine-Transcarbamylase Deficiency Product Portfolio
- 8.3.5 Promethera Biosciences SA Recent Developments
- 8.4 Selecta Biosciences Inc
- 8.4.1 Selecta Biosciences Inc Company Information
- 8.4.2 Selecta Biosciences Inc Business Overview
- 8.4.3 Selecta Biosciences Inc Ornithine-Transcarbamylase Deficiency Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Selecta Biosciences Inc Ornithine-Transcarbamylase Deficiency Product Portfolio
- 8.4.5 Selecta Biosciences Inc Recent Developments
- 8.5 Translate Bio Inc
- 8.5.1 Translate Bio Inc Company Information
- 8.5.2 Translate Bio Inc Business Overview
- 8.5.3 Translate Bio Inc Ornithine-Transcarbamylase Deficiency Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Translate Bio Inc Ornithine-Transcarbamylase Deficiency Product Portfolio
- 8.5.5 Translate Bio Inc Recent Developments
- 8.6 Ultragenyx Pharmaceutical Inc
- 8.6.1 Ultragenyx Pharmaceutical Inc Company Information
- 8.6.2 Ultragenyx Pharmaceutical Inc Business Overview
- 8.6.3 Ultragenyx Pharmaceutical Inc Ornithine-Transcarbamylase Deficiency Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Ultragenyx Pharmaceutical Inc Ornithine-Transcarbamylase Deficiency Product Portfolio
- 8.6.5 Ultragenyx Pharmaceutical Inc Recent Developments
- 8.7 Unicyte AG
- 8.7.1 Unicyte AG Company Information
- 8.7.2 Unicyte AG Business Overview
- 8.7.3 Unicyte AG Ornithine-Transcarbamylase Deficiency Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Unicyte AG Ornithine-Transcarbamylase Deficiency Product Portfolio
- 8.7.5 Unicyte AG Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Ornithine-Transcarbamylase Deficiency Value Chain Analysis
- 9.1.1 Ornithine-Transcarbamylase Deficiency Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Ornithine-Transcarbamylase Deficiency Production Mode & Process
- 9.2 Ornithine-Transcarbamylase Deficiency Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Ornithine-Transcarbamylase Deficiency Distributors
- 9.2.3 Ornithine-Transcarbamylase Deficiency Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst